Literature DB >> 20634381

A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.

Qiufang Cheng1, Erik I Tucker, Meghann S Pine, India Sisler, Anton Matafonov, Mao-Fu Sun, Tara C White-Adams, Stephanie A Smith, Stephen R Hanson, Owen J T McCarty, Thomas Renné, András Gruber, David Gailani.   

Abstract

Mice lacking factor XII (fXII) or factor XI (fXI) are resistant to experimentally-induced thrombosis, suggesting fXIIa activation of fXI contributes to thrombus formation in vivo. It is not clear whether this reaction has relevance for thrombosis in pri mates. In 2 carotid artery injury models (FeCl(3) and Rose Bengal/laser), fXII-deficient mice are more resistant to thrombosis than fXI- or factor IX (fIX)-deficient mice, raising the possibility that fXII and fXI function in distinct pathways. Antibody 14E11 binds fXI from a variety of mammals and interferes with fXI activation by fXIIa in vitro. In mice, 14E11 prevented arterial occlusion induced by FeCl(3) to a similar degree to total fXI deficiency. 14E11 also had a modest beneficial effect in a tissue factor-induced pulmonary embolism model, indicating fXI and fXII contribute to thrombus formation even when factor VIIa/tissue factor initiates thrombosis. In baboons, 14E11 reduced platelet-rich thrombus growth in collagen-coated grafts inserted into an arteriovenous shunt. These data support the hypothesis that fXIIa-mediated fXI activation contributes to thrombus formation in rodents and primates. Since fXII deficiency does not impair hemostasis, targeted inhibition of fXI activation by fXIIa may be a useful antithrombotic strategy associated with a low risk of bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634381      PMCID: PMC2981546          DOI: 10.1182/blood-2010-02-270918

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation.

Authors:  H N Bradford; R A Pixley; R W Colman
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.

Authors:  Thomas Renné; David Gailani; Joost C M Meijers; Werner Müller-Esterl
Journal:  J Biol Chem       Date:  2001-11-30       Impact factor: 5.157

3.  High levels of coagulation factor XI as a risk factor for venous thrombosis.

Authors:  J C Meijers; W L Tekelenburg; B N Bouma; R M Bertina; F R Rosendaal
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

4.  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Authors:  Li He; Cristina P Vicente; Randal J Westrick; Daniel T Eitzman; Douglas M Tollefsen
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

5.  Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates.

Authors:  Andras Gruber; Stephen R Hanson
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

6.  Protection against thrombosis in mice lacking PAR3.

Authors:  Ethan J Weiss; Justin R Hamilton; Katy E Lease; Shaun R Coughlin
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

7.  Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo.

Authors:  Hans-Ulrich Pauer; Thomas Renné; Bernhard Hemmerlein; Tobias Legler; Saskia Fritzlar; Ibrahim Adham; Werner Müller-Esterl; Guenter Emons; Ulrich Sancken; Wolfgang Engel; Peter Burfeind
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

8.  Factor XI contributes to thrombin generation in the absence of factor XII.

Authors:  Dmitri V Kravtsov; Anton Matafonov; Erik I Tucker; Mao-Fu Sun; Peter N Walsh; Andras Gruber; David Gailani
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

Review 9.  Factor XI deficiency in humans.

Authors:  U Seligsohn
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

10.  Molecular cloning and biochemical characterization of rabbit factor XI.

Authors:  Dipali Sinha; Mariola Marcinkiewicz; David Gailani; Peter N Walsh
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

View more
  114 in total

1.  Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

Authors:  F M Rabey; R S V S Gadepalli; S Diano; Q Cheng; T Tabrizian; D Gailani; J M Rimoldi; Z Shariat-Madar
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  Biorheology of platelet activation in the bloodstream distal to thrombus formation.

Authors:  Jevgenia Zilberman-Rudenko; Asako Itakura; Jeevan Maddala; Sandra M Baker-Groberg; Ralf Vetter; Erik I Tucker; András Gruber; Christoph Gerdes; Owen J T McCarty
Journal:  Cell Mol Bioeng       Date:  2016-05-26       Impact factor: 2.321

3.  Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Lawrence L Johnson; Erik I Tucker; Andras Gruber; David Gailani; Stephen T Smiley
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

4.  Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Authors:  Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

Review 5.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

Review 6.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

7.  Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate.

Authors:  Patricia H Alvarenga; Xueqing Xu; Fabiano Oliveira; Andrezza C Chagas; Clarissa R Nascimento; Ivo M B Francischetti; Maria A Juliano; Luiz Juliano; Julio Scharfstein; Jesus G Valenzuela; José M C Ribeiro; John F Andersen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-03       Impact factor: 8.311

8.  Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate.

Authors:  Reiner K Mailer; Mikel Allende; Marco Heestermans; Michaela Schweizer; Carsten Deppermann; Maike Frye; Giordano Pula; Jacob Odeberg; Mathias Gelderblom; Stefan Rose-John; Albert Sickmann; Stefan Blankenberg; Tobias B Huber; Christian Kubisch; Coen Maas; Stepan Gambaryan; Dmitri Firsov; Evi X Stavrou; Lynn M Butler; Thomas Renné
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

9.  Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.

Authors:  Jevgenia Zilberman-Rudenko; Stéphanie E Reitsma; Cristina Puy; Rachel A Rigg; Stephanie A Smith; Erik I Tucker; Robert Silasi; Alona Merkulova; Keith R McCrae; Coen Maas; Rolf T Urbanus; David Gailani; James H Morrissey; András Gruber; Florea Lupu; Alvin H Schmaier; Owen J T McCarty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

10.  Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.

Authors:  Christina U Lorentz; Norah G Verbout; Michael Wallisch; Matthew W Hagen; Joseph J Shatzel; Sven R Olson; Cristina Puy; Monica T Hinds; Owen J T McCarty; David Gailani; András Gruber; Erik I Tucker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.